leadf
logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience says volume of DehydraTECH-enabled CBD powders processed is exceeding all expectations

As of October 21, Lexaria has already processed around 4.2 million servings and has confirmed purchase orders to process a total of over 8 million servings during the current fiscal quarter

Cannabis leaf overlaid with CBD molecular structure
Lexaria's DehydraTECH technology masks unwanted tastes, improves onset speed, and increases the bioavailability of active pharmaceutical ingredients

Lexaria Bioscience Corp (OTCQX:LXRP) (CSE:LXX) announced Thursday that the volume of servings produced of its patented DehydraTECH-enabled CBD powders is expected to hit for 500% growth over the previous quarter.

On September 23, the company told investors it had received purchase orders for 4.4 million CBD servings of the powder, to be processed during the company’s fiscal first quarter of 2021, September 1 to November 30.

Now, processing rates have exceeded expectations, the company said, and as of October 21, Lexaria has already processed approximately 4.2 million servings and has confirmed purchase orders to process a total of over 8 million servings during the current quarter.

READ: Lexaria Bioscience wins first European patent related to its DehydraTECH technology

That new estimate represents over 500% volume growth from approximately 1.2 million CBD servings processed in the fiscal fourth quarter ended August 31, which itself reflected growth of 71% from the fiscal third quarter. One serving generally ranges from 10mg to 25mg of CBD, utilizing the company’s DehydraTECH processes.

Lexaria’s expectation is to produce at least 56 million servings during the 2021 calendar year, and, citing communication from existing customers, it says that number may prove to be conservative. However, these indicative orders do not include any additional demand from prospective future clients, Lexaria added.

The company’s business divisions include both technology licensing, in which corporate licensees implement DehydraTECH under license within their own facilities under royalty agreements, as well as also B2B operations where clients purchase pre-processed DehydraTECH CBD-powders manufactured at a Lexaria-contracted GMP-certified food facility for shipment back to the client for integration into their final product formats. 

The Kelowna, British Columbia-based company’s DehydraTECH technology masks unwanted tastes, improves onset speed, and increases the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Lexaria Bioscience Corp.

Price: 0.35 CAD

CSE:LXX
Market: CSE
Market Cap: $31.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Lexaria Bioscience proves technology works in enhancing oral delivery of...

Lexaria Bioscience (OTCQX:LXRP-CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company has announced that its DehydraTECH technology significantly improved delivery in study animals of representative drugs from two classes of antiviral therapies. Bunka telling...

3 days, 10 hours ago

2 min read